Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
GASTROENTEROLOGY / CLINICAL RESEARCH
Early and simple laboratory markers of poor outcome in children with inflammatory bowel disease
1
Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology, Medical University of Bialystok, Poland
Submission date: 2025-03-26
Final revision date: 2025-04-27
Acceptance date: 2025-05-11
Online publication date: 2025-06-23
Corresponding author
Katarzyna Zdanowicz
Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology Medical University of Bialystok, Poland
Department of Pediatrics, Gastroenterology, Hepatology, Nutrition, Allergology and Pulmonology Medical University of Bialystok, Poland
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Personalized medicine in inflammatory bowel disease (IBD) aims to achieve maximum effectiveness through rapid induction and maintenance of remission. To achieve this goal, reliable predictors of disease course are needed. The aim of this study was to identify early markers of IBD’s poor course understood as the need for anti-tumor necrosis factor (anti-TNF-α) .
Material and methods:
We analyzed the clinical, laboratory, radiological, and endoscopic data of children with IBD. These parameters were assessed at the time of diagnosis (T0) and 8–12 weeks (T1) after the start of induction therapy. The results of patients who did not require anti-TNF-α treatment were compared to children who needed such treatment during the 2-year observation time.
Results:
58.14% of patients with Crohn’s disease (CD) and 31.71% of patients with ulcerative colitis (UC) required biological therapy. Patients with CD and UC receiving biological therapy, compared with those without, differed in selected clinical and laboratory parameters both at T0 and T1. In multivariate analysis, the risk of anti-TNF-α therapy in patients with CD was associated with the lack of normalization of mean corpuscular volume (MCV) and Pediatric Crohn’s Disease Activity Index (PCDAI). In patients with UC, higher albumin levels reduced this risk.
Conclusions:
In children with IBD, disease activity and concentrations of selected biochemical parameters assessed within 3 months after diagnosis may be helpful in predicting a poor outcome of CD and UC.
Personalized medicine in inflammatory bowel disease (IBD) aims to achieve maximum effectiveness through rapid induction and maintenance of remission. To achieve this goal, reliable predictors of disease course are needed. The aim of this study was to identify early markers of IBD’s poor course understood as the need for anti-tumor necrosis factor (anti-TNF-α) .
Material and methods:
We analyzed the clinical, laboratory, radiological, and endoscopic data of children with IBD. These parameters were assessed at the time of diagnosis (T0) and 8–12 weeks (T1) after the start of induction therapy. The results of patients who did not require anti-TNF-α treatment were compared to children who needed such treatment during the 2-year observation time.
Results:
58.14% of patients with Crohn’s disease (CD) and 31.71% of patients with ulcerative colitis (UC) required biological therapy. Patients with CD and UC receiving biological therapy, compared with those without, differed in selected clinical and laboratory parameters both at T0 and T1. In multivariate analysis, the risk of anti-TNF-α therapy in patients with CD was associated with the lack of normalization of mean corpuscular volume (MCV) and Pediatric Crohn’s Disease Activity Index (PCDAI). In patients with UC, higher albumin levels reduced this risk.
Conclusions:
In children with IBD, disease activity and concentrations of selected biochemical parameters assessed within 3 months after diagnosis may be helpful in predicting a poor outcome of CD and UC.
REFERENCES (35)
1.
Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010; 139: 1147-55.
2.
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn’s and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67: 257-91.
3.
Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion 2012; 85: 308-19.
4.
de Laffolie J, Zimmer KP, Sohrabi K, Hauer AC. Running behind “POPO” - Impact of predictors of poor outcome for treatment stratification in pediatric crohn’s disease. Front Med 2021; 8: 644003.
5.
Lee YM, Kim ES, Choi S, et al. Fecal calprotectin at postinduction is capable of predicting persistent remission and endoscopic healing after 1 year of treatment with infliximab in pediatric patients with Crohn’s disease. Gut Liver 2024; 18: 498-508.
6.
Levine A, Turner D, Pfeffer Gik T, et al. Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn’s disease: evaluation of the porto IBD group “growth relapse and outcomes with therapy” (GROWTH CD) study. Inflamm Bowel Dis 2014; 20: 278-85.
7.
van Rheenen PF, Aloi M, Assa A, et al. The medical management of paediatric Crohn’s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis 2021; 15: jjaa161.
8.
Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 67: 292-310.
9.
Guariso G, Gasparetto M. Treating children with inflammatory bowel disease: current and new perspectives. World J Gastroenterol 2017; 23: 5469-85.
10.
Claßen M, de Laffolie J, Schnell A, Sohrabi K, Hoerning A. Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease – data from the multicenter CEDATA-GPGE registry study. Front Pediatr 2022; 10: 903677.
11.
Kim HJ, Oh SH, Lee SH, et al. risk factors for disease behavior evolution and efficacy of biologics in reducing progression in pediatric patients with nonstricturing, nonpenetrating Crohn’s disease at diagnosis: a single-center experience in Korea. Gut Liver 2021; 15: 851-7.
12.
Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet 2015; 386: 1825-34.
13.
Noor NM, Lee JC, Bond S, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 2024; 9: 415-27.
14.
Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr 2014; 58: 795-806.
15.
Turner D, Griffiths AM, Mack D, et al. Assessing disease activity in ulcerative colitis: patients or their physicians? Inflamm Bowel Dis 2010; 16: 651-6.
16.
Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-32.
17.
Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 1660-6.
18.
Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis 2011; 17: 1314-21.
19.
Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12.
20.
Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014; 8: 1179-207.
21.
Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106: 574-88.
22.
Olbjørn C, Nakstad B, Småstuen MC, Thiis-Evensen E, Vatn MH, Perminow G. Early anti-TNF treatment in pediatric Crohn’s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients. Scand J Gastroenterol 2014; 49: 1425-31.
23.
Olbjørn C, Cvancarova Småstuen M, Thiis-Evensen E, Nakstad B, Vatn MH, Perminow G. Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy. Scand J Gastroenterol 2017; 52: 414-9.
24.
Hyams JS, Davis Thomas S, Gotman N, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet 2019; 393: 1708-20.
25.
Gasparetto M, Wong-Spracklen V, Torrente F, et al. Early treatment response predicts outcome in paediatric ulcerative colitis: gastroenterology: inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2018; 67: 217-20.
26.
Krawiec P, Pac-Kożuchowska E. Biomarkers and hematological indices in the diagnosis of iron deficiency in children with inflammatory bowel disease. Nutrients 2020; 12: 1358.
27.
Daniluk U, Daniluk J, Krasnodebska M, Lotowska JM, Sobaniec-Lotowska ME, Lebensztejn DM. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn’s disease. Adv Med Sci 2019; 64: 9-14.
28.
Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570-83.
29.
Matuszczyk M, Meglicka M, Wiernicka A, et al. Effect of the Crohn’s Disease Exclusion Diet (CDED) on the fecal calprotectin level in children with active Crohn’s disease. J Clin Med 2022; 11: 4146.
30.
Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014; 12: 103-17.
31.
Hyams JS, Davis S, Mack DR, et al. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol 2017; 2: 855-68.
32.
Zhang Y, Xu F, Li Y, Chen B. C-reactive protein-to-albumin ratio and neutrophil-to-albumin ratio for predicting response and prognosis to infliximab in ulcerative colitis. Front Med 2024; 11: 1349070.
33.
Zhou Z, Zhang Y, Pan Y, et al. A novel neutrophil-based biomarker to monitor disease activity and predict response to infliximab therapy in patients with ulcerative colitis. Front Med 2022; 9: 872831.
34.
Zdanowicz K, Pietrowska K, Lebensztejn DM, et al. Evaluation of microbiome composition combined with serum untargeted metabolomic profiling in newly diagnosed children with inflammatory bowel disease. Arch Med Sci 2025; 21: 416-24.
35.
Yasuda R, Arai K, Kudo T, et al. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: a multicenter study in Japan. J Gastroenterol Hepatol 2023; 38: 1131-9.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
